Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMYBV3G)

Drug Name
Paricalcitol Drug Info
Synonyms
Paracalcin; Zemplar; Abbott brand of paricalcitol; Paricalcitol [USAN]; Ab 122358; ABT-358; Zemplar (TN); Paricalcitol (USAN/INN); Paricalcitol, 19-nor-(OH)2-vitD2, paracalcin; (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol; (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol; (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol; 19-Nor-1,25-(OH)2D2; 19-Nor-1-alpha,25-dihydroxyvitamin D2; 19-Nor-1alpha,25-dihydroxyvitamin D2; 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol,(1alpha,3beta,7E,22E)
Therapeutic ClassParasympathomimetics
Cross-matching ID
PubChem CID
5281104
ChEBI ID
CHEMBL7931
CAS Number
CAS 131918-61-1
TTD Drug ID
D0N1TP
ACDINA Drug ID
D00509

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Hypertrophic cardiomyopathy 2.36 0.00e+0 81/90 (90%) TPM4;TTN;DES;...
Dilated cardiomyopathy 2.26 0.00e+0 86/96 (89.58%) TPM4;TTN;GNAS;...
Focal adhesion 2.21 0.00e+0 180/201 (89.55%) MET;VEGFC;LAMB1;...
IL-17 signaling pathway 2.05 8.18e-3 84/94 (89.36%) CXCL2;MAPK13;MUC5B;...
ECM-receptor interaction 1.96 6.54e-3 80/88 (90.91%) LAMB1;FN1;TNC;...
Arginine and proline metabolism 1.90 1.82e-2 39/50 (78%) CKM;ALDH2;CKMT2;...
TNF signaling pathway 1.86 2.18e-2 103/112 (91.96%) CXCL2;VEGFC;MAPK13;...
Gap junction 1.82 2.18e-2 72/88 (81.82%) LPAR1;GNAI1;GNAS;...
Regulation of actin cytoskeleton 1.82 1.94e-2 185/218 (84.86%) LPAR1;FN1;MYLK;...
Proteoglycans in cancer 1.81 1.75e-2 172/205 (83.9%) MET;MAPK13;FN1;...
Amino sugar and nucleotide sugar metabolism 1.79 1.98e-2 38/48 (79.17%) GALE;HK2;GPI;...
Citrate cycle (TCA cycle) 1.78 2.09e-2 30/30 (100%) DLD;IDH2;ACO1;...
Pathogenic Escherichia coli infection 1.77 1.93e-2 152/197 (77.16%) LPAR1;MAPK13;NFKBIA;...
PI3K-Akt signaling pathway 1.76 2.03e-2 317/354 (89.55%) LPAR1;MET;VEGFC;...
Pertussis 1.76 2.04e-2 64/76 (84.21%) GNAI1;MAPK13;IL1A;...
Amoebiasis 1.76 1.91e-2 99/102 (97.06%) CXCL2;LAMB1;FN1;...
Steroid biosynthesis 1.73 2.25e-2 19/20 (95%) SOAT1;MSMO1;CYP51A1;...
Rap1 signaling pathway 1.73 2.12e-2 184/210 (87.62%) LPAR1;MET;GNAI1;...
Protein export 1.72 2.12e-2 17/23 (73.91%) SRP54;SRPRA;OXA1L;...
Glycolysis / Gluconeogenesis 1.68 3.00e-2 56/67 (83.58%) DLD;ALDH3A1;ENO2;...
Tryptophan metabolism 1.66 3.43e-2 35/42 (83.33%) KYNU;DLD;ALDH2;...
Histidine metabolism 1.66 3.42e-2 16/22 (72.73%) ALDH3A1;ALDH2;ALDH3B1;...
Legionellosis 1.66 3.32e-2 51/57 (89.47%) CXCL2;NFKBIA;CXCL1;...
Pentose phosphate pathway 1.64 3.77e-2 25/30 (83.33%) PGD;G6PD;FBP1;...
Bacterial invasion of epithelial cells 1.63 4.45e-2 59/77 (76.62%) MET;FN1;CAV2;...
Neomycin, kanamycin and gentamicin biosynthesis 1.63 4.36e-2 5/5 (100%) HK2;HK3;HKDC1;...
Complement and coagulation cascades 1.62 4.48e-2 76/85 (89.41%) F3;SERPINB2;CD55;...
Cardiac muscle contraction 1.62 4.40e-2 64/87 (73.56%) TPM4;TNNC1;ACTC1;...
Epithelial cell signaling in Helicobacter pylori infect... 1.61 4.55e-2 62/70 (88.57%) MET;CXCL2;MAPK13;...
Small cell lung cancer 1.61 4.55e-2 90/92 (97.83%) LAMB1;FN1;NFKBIA;...
Porphyrin and chlorophyll metabolism -1.71 3.70e-2 23/43 (53.49%) HMOX2;FECH;HEPH;...
Ribosome -1.72 3.51e-2 113/158 (71.52%) RPS27A;RPL10A;FAU;...
Butanoate metabolism -1.73 4.01e-2 23/28 (82.14%) ACADS;L2HGDH;GAD2;...
Antigen processing and presentation -1.75 3.65e-2 60/78 (76.92%) KIR2DL1;CD8A;KLRC3;...
Allograft rejection -1.75 4.38e-2 32/38 (84.21%) TNF;HLA-E;HLA-C;...
Mineral absorption -1.84 1.75e-2 48/60 (80%) ATP2B2;ATOX1;MT1HL1;...
Ribosome biogenesis in eukaryotes -1.85 2.19e-2 52/108 (48.15%) TCOF1;MDN1;GAR1;...
Asthma -1.99 1.75e-2 25/31 (80.65%) TNF;CD40;CD40LG;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.03uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.03uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.125uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.125uM - 10uM 24H